898563-26-3

Basic information

• Product Name: 4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenol
• Synonyms: 4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenol
• CAS NO: 898563-26-3
• Molecular Formula: C₁₅H₁₃N₃O
• Molecular Weight: 251.28322
• Mol File: 898563-26-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenol(898563-26-3)
• EPA Substance Registry System: 4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenol(898563-26-3)

Safety Data

• Hazardous Substances Data: 898563-26-3(Hazardous Substances Data)

Usage

Classification

Pyrazole

Structure

Phenolic compound with a pyrazole ring and a pyridinyl group attached

Biological activities

Antifungal, antibacterial, anti-inflammatory

Potential uses

Pharmaceuticals, agrochemicals

Additional properties

Potential antioxidant, enzyme inhibitor

Ongoing research

Exploring potential applications and mechanisms of action

Upstream product

• 898563-25-2 4-[3-(4-benzyloxy-phenyl)-1-methyl-1H-pyrazol-4-yl]-pyridine 
• 1486-51-7 p-(benzyloxy)benzoic acid 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 60-34-4 methylhydrazine 
• 171001-06-2 1-(4-(benzyloxy)phenyl)-2-(pyridin-4-yl)ethanone 
• 252199-28-3 4-(benzyloxy)-N-methoxy-N-methylbenzamide 
• 1486-50-6 4-(benzyloxy)benzoic acid chloride 

Downstream Products

• 1422841-34-6 C₂₆H₂₂N₄O₂ 
• 1422841-39-1 C₂₆H₂₂N₄O₂ 
• 1422841-40-4 C₂₆H₂₂N₄O₂ 
• 1422841-41-5 C₂₆H₂₂N₄O₂ 
• 1521139-21-8 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine 
• 1521139-28-5 3-methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one 

Relevant articles and documents

RADIOLABELED PDE10A LIGANDS

Compounds of formula (I) are disclosed Compounds of formula (I) are useful in treating conditions and disorders prevented by or ameliorated by PDE10A ligands. Radiolabeled compounds of formula (I) are also useful as diagnostic tools as PDE10A positron emi

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3- yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia

By utilizing structure-based drug design (SBDD) knowledge, a novel class of phosphodiesterase (PDE) 10A inhibitors was identified. The structure-based drug design efforts identified a unique "selectivity pocket" for PDE10A inhibitors, and interactions within this pocket allowed the design of highly selective and potent PDE10A inhibitors. Further optimization of brain penetration and drug-like properties led to the discovery of 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920). This PDE10A inhibitor is the first reported clinical entry for this mechanism in the treatment of schizophrenia.

Heteroaromatic quinoline compounds

The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.